• August 15, 2020 

    Maintenance Avelumab Improves Survival in Advanced Bladder CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial for certain patients with advanced urothelial carcinoma, overall survival was prolonged by about 30% by using supportive care plus maintenance treatment with the drug avelumab, versus supportive care alone.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    In a First, Proton Therapy Bests Radiotherapy in an RCTBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial that compared proton beam therapy with standard radiotherapy for esophageal cancer, the two treatments were found to be virtually identical in terms of progression-free survival, overall survival, and quality of life.

    Go to full news article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    ATIM-14. Results of Phase II Clinical Trial of Oncolytic Herpes Virus G47∆ in Patients with GlioblastomaBookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    Lung cancer at ASCO20 VirtualBookmark

    George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology featured presentations on several different targeted therapies that appear to provide improved outcomes for lung cancer patients.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    ICI for Resected Stage IV MelanomaBookmark

    George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial for metastatic melanoma patients, a combination of the drugs nivolumab and ipilimumab (both “immune checkpoint inhibitors,” or ICIs) outperformed nivolumab on its own, and nivolumab on its own outperformed a placebo.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    Key Studies in Metastatic Breast Cancer From ASCO 2020Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    This year’s virtual meeting of the American Society of Clinical Oncology (ASCO) featured five important studies on metastatic breast cancer, as outlined in this video.

    Go to full article and video published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 14, 2020 

    Is Polio the Answer to Curing Brain Tumors?Bookmark

    George Lundberg, MD

    Article from WKYC Studios curated by Editor in Chief George Lundberg, MD, who notes: 

    An experimental treatment in which the virus that causes polio is directly injected into glioblastoma (GBM) tissue has shown some promise, as reported in the New England Journal of Medicine in 2018. This news story from WKYC provides a partial update from an ongoing subsequent clinical trial.

    Go to full article published by WKYC Studios.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 14, 2020 

    A Phase II Randomized, Multicenter, Open-Label Trial of Continuing Adjuvant Temozolomide Beyond Six Cycles in Patients With Glioblastoma (GEINO 14-01)Bookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    These clinical trial results suggest that six cycles of temozolomide is as effective as 12 for patients with glioblastoma and produces fewer side effects.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 7, 2020 

    Final Results from KEYNOTE-100 Show Promise for Pembrolizumab MonotherapyBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:

    Treatment with pembrolizumab (brand name Keytruda) on its own shows modest responses in patients with recurrent ovarian cancer.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • May 30, 2020 

    Atezolizumab Plus Bevacizumab vs Sorafenib in Treatment-Naive Patients With Unresectable Hepatocellular CarcinomaBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial, a combination of the drugs atezolizumab and bevacizumab improved both progression-free survival and overall survival in advanced hepatocarcinoma (the most common form of liver cancer), with fewer adverse effects. These findings were reported in the New England Journal of Medicine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.